Reading APYX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track APYX free→Reading APYX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track APYX free→NASDAQHealth CareMedical DevicesSnapshot 2026-06-15
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is neutral, and management's recent track record has been steady. The company was unprofitable over the past year, so its earnings quality can't be assessed. Risk is high, and the sector backdrop is a headwind, while compared with sector peers, it is above typical. Peer multiples imply a price about 22% above where it trades (it looks cheap on this basis); the read is fair, but weakening. This assessment is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 2 valuation methods, at three horizons. Current price $4.60. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $4.60 APYX trades at 4× p/s, in line with its 3× p/s peer median. Our $5.54 fair value reflects that, medium confidence. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The price implies about 17% below a flat-multiple fair value, below our forecast of about 20%. This describes what's priced in, not a forecast of the move.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
Only a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 50% of the time over the next year (vs 57% for the rest of the cohort, n=3115).
Over the trailing year it converted 0.86x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, Fed net liquidity, long-term interest rates, real (inflation-adjusted) rates.
1 material management or governance event in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated stable grew net income 56% of the time over the next year (vs 52% for the rest of the cohort, n=618).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $-0.09 → $-0.09 (+2.8% / 30d). 4 raised, 0 cut, 4 covering analysts.
0 upgrades, 0 downgrades / 30d. 100% of analysts rate Buy.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$242.
How much price usually moves either way.
On a bad day, this stock has moved -$695.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $3,659.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-15
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: If sector growth speeds up, Apyx could do better. This may improve its outlook.
Confirms:Health Care sector revenue growth exceeds 10% year over year.
Disproves:Sector revenue growth remains below 10% year over year.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for APYX yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Results of Operations and Financial Condition On May 7, 2026, Apyx Medical Corporation (the "Company") issued a press release reporting on its results of operations for the first quarter ended March 31, 2026. A copy of that press release is attached hereto as Exhibit 99.1 and incorporated by reference herein. This information is intended to be furnished under
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Looks more expensive than peers.
Self-history needs ~20 months of data.
Trailing four: 2023-Q2, 2023-Q3, 2024-Q1, 2024-Q2
A side-by-side read on sector standing, valuation, and risk versus Health Care Equipment.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
APYX Apyx Medical Corp | Typical Show detailsSector percentile: 70 of 100 | fair | high |
ABT Abbott Laboratories | Above typical Show detailsSector percentile: 94 of 100 | fair | moderate |
ISRG Intuitive Surgical | Above typical Show detailsSector percentile: 94 of 100 | expensive | moderate |
SYK Stryker Corporation | Above typical Show detailsSector percentile: 71 of 100 | fair | moderate |
MDT Medtronic | Above typical Show detailsSector percentile: 89 of 100 | fair | moderate |
Not investment advice. As of 2026-06-15.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-15.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Management has raised the total revenue guidance for FY2026 to a range of $59.0 million to $60.0 million.
Stated in 2 of last 2 quarters. Revenue guidance increased from $57.5M-$58.5M to $59.0M-$60.0M, indicating management's confidence in growth. However, actual revenue in 2026-Q1 was $12.49M, down from $19.16M in 2025-Q4, showing limited progress towards the higher guidance.
“Raised total revenue guidance for FY2026 to a range of $59.0 million to $60.0 million.”
“Expect FY2026 total revenue in the range of $57.5 million to $58.5 million.”
Focus on improving operating income, which has fluctuated over recent quarters.
Stated in 3 of last 3 quarters. Operating income was -$911,000 in 2026-Q1, compared to $11,000 in 2025-Q4, indicating a decline. Despite management's focus, the trajectory shows limited progress in improving operating income.
Management aims to achieve positive cash flow from operations, which has been negative in recent quarters.
Stated in 3 of last 3 quarters. Cash from operating activities improved from -$3,536,000 in 2025-Q3 to -$572,000 in 2026-Q1, showing progress towards positive cash flow. However, it remains negative, indicating ongoing challenges.
Results of Operations and Financial Condition On March 10, 2026, Apyx Medical Corporation (the "Company") issued a press release reporting on its results of operations for the fourth quarter and year ended December 31, 2025. A copy of that press release is attached hereto as Exhibit 99.1 and incorporated by reference herein. This information is intended to be furnished under
Results of Operations and Financial Condition On January 12, 2026, Apyx Medical Corporation (the “Company”) issued a press release reporting on its preliminary revenue results for the fourth quarter and year ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this report (including Exhibit 99.1) is being furnished pursuant to
Entry into a Material Definitive Agreement. On November 18, 2025, Apyx Medical Corporation (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Lucid Capital Markets, LLC (the “Underwriter”) pursuant to which the Company will issue and sell to the Underwriter pursuant to the Underwriting Agreement 2,762,431 shares (the “Shares”) of common stock, par value $0.001 per share (the “Common Stock”) at an offering price of $3.62 and grant to the Underwriter an o…
Results of Operations and Financial Condition On November 6, 2025, Apyx Medical Corporation (the "Company") issued a press release reporting on its results of operations for the third quarter ended September 30, 2025. A copy of that press release is attached hereto as Exhibit 99.1 and incorporated by reference herein. This information is intended to be furnished under
“Operating income was -$911,000 in 2026-Q1.”
“Operating income was $11,000 in 2025-Q4.”
“Operating income was -$832,000 in 2025-Q3.”
“Cash from operating activities was -$572,000 in 2026-Q1.”
“Cash from operating activities was -$2,530,000 in 2025-Q4.”
“Cash from operating activities was -$3,536,000 in 2025-Q3.”